Phospho-GATA1 (S142) Antibody

What is GATA1 and why is phosphorylation at serine 142 significant?

GATA1 (also known as ERYF1, GF1, or Erythroid transcription factor) is a critical transcription factor that serves as a general switch for erythroid development. It belongs to the GATA family of transcription factors and binds to DNA sites with the consensus sequence 5'-[AT]GATA[AG]-3' within regulatory regions of globin genes and other genes expressed in erythroid cells .

GATA1 functions as both a transcriptional activator and repressor. It activates the transcription of genes involved in erythroid differentiation of K562 erythroleukemia cells, including HBB, HBG1/2, ALAS2, and HMBS . It is essential for the generation of erythroid, megakaryocytic, eosinophilic, and mast cell lineages .

Phosphorylation at serine 142 (S142) is one of seven serine residues (26, 49, 72, 142, 178, 187, and 310) where GATA1 can be phosphorylated, with S142 being constitutively phosphorylated along with five other serine residues (only S310 is inducibly phosphorylated during erythroid differentiation) . While research has shown that phosphorylation at residues 72, 142, and 310 is not essential for steady-state hematopoiesis in vivo, the modification may play regulatory roles in certain cellular contexts or stress conditions .

What are the validated applications for Phospho-GATA1 (S142) antibodies?

Phospho-GATA1 (S142) antibodies have been validated for multiple applications including:

• Western Blot (WB): Typically used at dilutions of 1:500-1:1000

• Immunohistochemistry (IHC-P): Effective at dilutions of 1:50-1:200 for paraffin-embedded tissues

• Immunoprecipitation (IP): Used at dilutions of 1:50-1:200

• Enzyme-Linked Immunosorbent Assay (ELISA): Validated for qualitative determination of phosphorylated GATA1

• Immunofluorescence (IF): Appropriate for cell localization studies

The antibodies have been tested with human, mouse, and rat samples, with confirmed reactivity across these species .

How do researchers distinguish between phosphorylated and non-phosphorylated GATA1 in experiments?

To distinguish between phosphorylated and non-phosphorylated GATA1:

• Specific antibodies: Use of antibodies specifically targeting phosphorylated GATA1 at S142, often generated using synthetic phosphopeptides as immunogens .

• Control experiments: Include parallel experiments with antibodies recognizing total GATA1 (regardless of phosphorylation state) .

• Phosphatase treatment: Samples can be treated with phosphatases to remove phosphorylation, followed by comparison with untreated samples.

• Peptide competition assays: Preincubation of the antibody with the phosphorylated peptide should abolish signal, while preincubation with non-phosphorylated peptide should not affect antibody binding. This validates phospho-specificity, as demonstrated in the breast carcinoma tissue staining example where antibody preincubated with synthesized phosphopeptide shows no staining .

• ELISA normalization methods: For ELISA applications, multiple normalization approaches can be used:

  • Anti-GAPDH antibody serves as an internal positive control

  • Crystal Violet whole-cell staining determines cell density for normalization

  • Anti-GATA1 antibody (detecting total GATA1) allows normalization against total GATA1 levels

How does phosphorylation at S142 compare functionally with other GATA1 phosphorylation sites?

Research on GATA1 phosphorylation sites reveals interesting comparative insights:

• Constitutive vs. inducible phosphorylation: S142 is constitutively phosphorylated along with five other serine residues (26, 49, 72, 178, 187), while S310 is phosphorylated following induction of erythroid differentiation .

• Functional redundancy: Studies using knock-in mice with serine-to-alanine mutations at S310 alone (Gata1^S310A) or at residues 72, 142, and 310 together (Gata1^3SA) revealed that:

  • These phosphorylation sites are dispensable for steady-state hematopoiesis

  • Mice with these mutations had normal peripheral blood parameters

  • Their response to acute erythropoietic stress (phenylhydrazine-induced anemia) was normal

  • There was moderate decrease in BFU-E and CFU-E progenitor populations in adult bone marrow of triple mutants, but later-stage erythropoiesis was unperturbed

• Compensatory mechanisms: The research suggests that molecular consequences associated with loss of phosphorylation at residues 72, 142, and 310 can be compensated for in the in vivo environment .

This indicates that while S142 phosphorylation occurs consistently, its precise role may involve subtle regulatory functions that might become apparent only under specific conditions or in certain cellular contexts.

What are the optimal experimental conditions for detecting phosphorylated GATA1 at S142?

For optimal detection of phosphorylated GATA1 at S142:

• Sample preparation:

  • For protein extracts: Use phosphatase inhibitors in all buffers to preserve phosphorylation status

  • For tissues: Rapid fixation with phosphatase inhibitor-containing buffers is critical

  • For cell culture: Consider timing relative to cell signaling events that might affect phosphorylation status

• Antibody validation:

  • Use appropriate controls, including phosphopeptide competition assays

  • Include samples known to express or not express phosphorylated GATA1

• Application-specific conditions:

  • Western blot: Recommended dilutions of 1:500-1:1000

  • IHC-P: Optimal dilutions of 1:50-1:100 for paraffin-embedded tissues

  • IP: Effective dilutions of 1:50-1:200

• Detection systems:

  • For Western blots: HRP-conjugated secondary antibodies with appropriate substrate

  • For IHC/IF: Fluorescent or chromogenic detection systems depending on experimental needs

• Cell types: K562 erythroleukemia cells are commonly used models for GATA1 studies as they express GATA1 and undergo erythroid differentiation .

What experimental approaches can validate the specificity of Phospho-GATA1 (S142) antibodies?

To validate the specificity of Phospho-GATA1 (S142) antibodies, researchers should consider:

• Peptide competition assays: Preincubate antibody with synthetic phosphopeptide corresponding to the phosphorylation site. Specific antibodies will show abolished signal, as demonstrated in the human breast carcinoma tissue staining where antibody preincubated with synthesized phosphopeptide showed no staining .

• Phosphatase treatment: Treat samples with lambda phosphatase to remove phosphorylation and compare with untreated samples. Specific phospho-antibodies should show decreased or absent signal in phosphatase-treated samples.

• Genetic models:

  • Use GATA1 knockout cells as negative controls

  • Compare with cells expressing GATA1 with serine-to-alanine mutations at S142 (S142A) which cannot be phosphorylated

  • Use cells with GATA1 knockdown via siRNA as performed in studies of GATA1 function

• Multiple detection methods: Compare results across different applications (WB, IHC, IP) to ensure consistent specificity patterns.

• Cross-reactivity testing: Test the antibody against other phosphorylated proteins, particularly other GATA family members, to ensure specificity.

• Purification method verification: The most reliable antibodies are affinity-purified using epitope-specific phosphopeptide columns, with antibodies against non-phosphopeptides removed using non-phosphopeptide columns corresponding to the phosphorylation site .

What are the recommended protocols for using Phospho-GATA1 (S142) antibodies in Western blot analysis?

For optimal Western blot results with Phospho-GATA1 (S142) antibodies:

• Sample preparation:

  • Use fresh samples whenever possible

  • Include phosphatase inhibitors in lysis buffers (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate)

  • Maintain samples at 4°C during preparation

• Protein separation:

  • Use 10-12% SDS-PAGE gels for optimal resolution of GATA1 (approximately 43 kDa)

  • Include molecular weight markers spanning 25-55 kDa range

• Transfer conditions:

  • Use PVDF membrane for better protein retention

  • Transfer at lower voltage for longer time (e.g., 30V overnight at 4°C) to ensure complete transfer

• Blocking:

  • Block with 5% BSA in TBST (not milk, as it contains phosphatases that could reduce signal)

  • Block for 1 hour at room temperature or overnight at 4°C

• Antibody incubation:

  • Dilute primary antibody 1:500-1:1000 in 5% BSA/TBST

  • Incubate overnight at 4°C with gentle agitation

  • Wash thoroughly with TBST (at least 3 x 10 minutes)

  • Incubate with HRP-conjugated secondary antibody (typically 1:5000-1:10000) for 1 hour at room temperature

• Detection:

  • Use enhanced chemiluminescence (ECL) detection

  • Begin with shorter exposures (30 seconds) and increase as needed

• Controls:

  • Include positive control (e.g., erythroid or megakaryocytic cell line lysate)

  • Include negative control (e.g., phosphatase-treated sample)

  • Run parallel blot with antibody against total GATA1 for normalization

How can researchers effectively use Phospho-GATA1 (S142) antibodies in cell-based assays?

For cell-based assays with Phospho-GATA1 (S142) antibodies:

• Cell-Based ELISA:

  • The GATA1 (phospho Ser142) Cell Based ELISA Kit allows for detection of phosphorylated GATA1 and assessment of how stimulation conditions affect phosphorylation

  • The assay uses an indirect ELISA format where anti-GATA1 (phospho Ser142) antibodies capture phosphorylated GATA1, which is detected by HRP-conjugated secondary antibodies

  • Multiple normalization methods are available:
    a) Anti-GAPDH antibody serves as internal positive control
    b) Crystal Violet whole-cell staining determines cell density for normalization
    c) Anti-GATA1 antibody allows normalization against total GATA1 levels

• Immunofluorescence:

  • Fix cells with 4% paraformaldehyde (10 minutes at room temperature)

  • Permeabilize with 0.1% Triton X-100 in PBS (5 minutes)

  • Block with 1-3% BSA in PBS (30-60 minutes)

  • Incubate with primary antibody at recommended dilutions (typically 1:50-1:200)

  • Wash and incubate with fluorophore-conjugated secondary antibody

  • Counterstain nucleus with DAPI

  • Mount and observe using fluorescence microscopy

• HiChIP Assay:

  • For chromatin interaction studies, GATA1 antibodies can be used in HiChIP assays

  • These assays require careful optimization of fixation, digestion, and immunoprecipitation steps

  • A protocol adapted from research literature includes:
    a) Fixing 10×10^6 cells with 1% formaldehyde
    b) Lysing cells in HiC buffer
    c) Solubilizing nuclei and digesting with MboI
    d) Biotin filling and proximity ligation
    e) Immunoprecipitation with anti-GATA1 antibody
    f) Washing, elution, and analysis

What are common technical challenges with Phospho-GATA1 (S142) antibodies and how can they be addressed?

Common challenges and solutions when working with Phospho-GATA1 (S142) antibodies:

• Weak or no signal:

  • Ensure phosphorylation status is preserved with phosphatase inhibitors

  • Optimize antibody concentration (try higher concentrations initially)

  • Increase protein loading for Western blots

  • Use enhanced detection systems

  • Consider alternative epitope recovery methods for IHC

• High background:

  • Increase washing steps (number and duration)

  • Optimize blocking (try different blocking agents: BSA, normal serum, commercial blockers)

  • Dilute antibody further

  • Pre-absorb antibody with cell/tissue lysate lacking GATA1

  • Filter secondary antibody solution

• Non-specific bands in Western blot:

  • Use higher antibody dilution

  • Perform peptide competition assay to identify specific band

  • Compare with total GATA1 antibody for band alignment

  • Consider gradient gels for better resolution

• Cross-reactivity issues:

  • Validate antibody specificity with phosphopeptide competition assays

  • Use genetic models (GATA1 knockout or S142A mutant) as controls

  • Consider alternative antibody clones

• Variable results between experiments:

  • Standardize sample preparation procedures

  • Include internal loading controls

  • Maintain consistent antibody lots

  • Store antibody as recommended (aliquot and store at -20°C, avoid freeze-thaw cycles)

• Tissue-specific optimization:

  • Different tissues may require modified antigen retrieval methods for IHC

  • Adjust fixation protocols for different sample types

  • Optimize permeabilization for different cell types in immunofluorescence

How does GATA1 phosphorylation at S142 contribute to hematopoiesis and erythroid differentiation?

The role of GATA1 phosphorylation at S142 in hematopoiesis and erythroid differentiation has been investigated through genetic studies:

• Genetically modified mouse models: Research using knock-in mice with serine-to-alanine mutations at S310 alone (Gata1^S310A) or at residues 72, 142, and 310 together (Gata1^3SA) revealed:

  • These phosphorylation sites are not essential for steady-state hematopoiesis

  • Mice had normal peripheral blood parameters and hematocrit

  • No red blood cell abnormalities were observed in cytological examinations

  • The response to acute erythropoietic stress (phenylhydrazine-induced anemia) was normal

• Progenitor population effects: A moderate decrease in both erythroid burst-forming unit (BFU-E) and erythroid colony-forming unit (CFU-E) progenitor populations was observed only in the adult bone marrow of the triple mutant (Gata1^3SA)

• Later-stage erythropoiesis: Despite the decrease in progenitor populations, later-stage erythropoiesis was not perturbed, suggesting compensatory mechanisms

• Mechanistic implications: The research suggests that while phosphorylation at S142 occurs constitutively, its role may be subtle or context-dependent, and any molecular consequences associated with loss of phosphorylation can be compensated for in the in vivo environment

This indicates that S142 phosphorylation, while conserved, may play regulatory roles that are not essential under normal physiological conditions but might become important under specific circumstances or in certain cellular contexts.

What specific protein interactions are regulated by GATA1 phosphorylation at S142?

The specific protein interactions regulated by GATA1 phosphorylation at S142 are not fully characterized in the provided research, but GATA1 is known to form several protein complexes that may be influenced by its phosphorylation status:

• GATA1 protein complexes: GATA1 forms distinct activating and repressive complexes in erythroid cells:

  • The GATA1/FOG-1 complex is associated with repression

  • The multimeric GATA1/TAL-1/Ldb1/E2A/LMO2 complex binds to closely spaced GATA and E-box binding motifs and is associated with activation of erythroid genes like glycophorin A and the α-globin locus

• Complex identification methodology: Studies have identified GATA1 complexes using biotinylation tagging and mass spectrometry approaches, showing interactions with:

  • FOG-1, TAL-1, and Ldb1 which copurify with GATA1

  • TAL-1 antibodies specifically immunoprecipitating GATA1 and Ldb1

• Potential phosphorylation effects: While the specific effects of S142 phosphorylation on these interactions aren't detailed in the provided research, phosphorylation often regulates:

  • Protein-protein interaction affinities

  • Complex formation or dissociation

  • Nuclear localization or retention

  • DNA binding affinity

• Transcriptional activity: GATA1 functions as both an activator and repressor of different gene sets, and phosphorylation could potentially modulate this dual activity

Further targeted research would be needed to determine the specific impact of S142 phosphorylation on these protein interactions and whether it affects the formation, stability, or function of different GATA1 complexes.

How can researchers integrate phospho-GATA1 (S142) data with other chromatin and transcriptional analyses?

Researchers can integrate phospho-GATA1 (S142) data with other chromatin and transcriptional analyses through several approaches:

• Multi-omics integration strategies:

  • Combine phospho-GATA1 detection with RNA-seq to correlate phosphorylation status with gene expression changes

  • Integrate with ChIP-seq data to map genomic binding sites of phosphorylated GATA1

  • Correlate with proteomics data to identify protein complexes associated with phosphorylated vs. non-phosphorylated GATA1

• HiChIP assays:

  • HiChIP assays can be used to examine chromatin interactions mediated by GATA1

  • These analyses reveal mechanistic insights into chromatin rearrangements during development

  • The protocol involves fixation, nuclei isolation, digestion, biotin filling, proximity ligation, and immunoprecipitation with GATA1 antibodies

• Reporter gene assays:

  • Reporter gene assays can assess transcriptional activity

  • For example, pGL3-SLC4A1-promoter with either wild-type or mutated GATA1 binding sites can be used to measure GATA1 activity

  • Results can be correlated with phosphorylation status

• Cellular differentiation models:

  • Use of differentiation systems like K562 erythroleukemia cells or CD34+ erythroid differentiation culture

  • Track phospho-GATA1 levels during differentiation stages (e.g., Day 5 Ery-Pro and Day 12 Ery-Pre cells)

  • Correlate with stage-specific transcriptional programs

• siRNA approaches:

  • GATA1 knockdown via siRNA can be performed, as described in research protocols:

    • Purified Ery-Pro cells can be nucleofected with siRNA

    • Knockdown efficiency can be assessed using qRT-PCR

    • Results can be compared with phosphorylation status data

• Correlation with mutation effects:

  • Compare transcriptional profiles between wild-type and phospho-mutant (S142A) systems

  • Analyze differential expression patterns to identify genes specifically regulated by phosphorylated GATA1

These integrated approaches can provide a comprehensive understanding of how S142 phosphorylation affects GATA1 function in different cellular contexts and developmental stages.

What emerging technologies might enhance detection and functional analysis of phosphorylated GATA1?

Several emerging technologies could enhance detection and functional analysis of phosphorylated GATA1:

• Proximity ligation assays (PLA):

  • These assays can detect protein-protein interactions in situ with high sensitivity

  • Could be used to identify interaction partners specific to phosphorylated GATA1

  • Would allow visualization of interactions in specific cellular compartments

• Mass spectrometry-based phosphoproteomics:

  • Targeted proteomics approaches can quantify specific phosphorylation sites

  • Would enable absolute quantification of phosphorylation stoichiometry

  • Could identify additional, previously uncharacterized phosphorylation sites

• Single-cell technologies:

  • Single-cell proteomics to examine heterogeneity in GATA1 phosphorylation

  • Single-cell transcriptomics to correlate phosphorylation status with gene expression patterns

  • Single-cell multiomic approaches combining protein and RNA measurements

• CRISPR-based technologies:

  • CRISPR activation/repression systems to modulate GATA1 expression

  • Base editing to introduce phosphomimetic mutations (S142D or S142E)

  • Prime editing for precise modification of phosphorylation sites

• Live-cell imaging approaches:

  • Phospho-specific fluorescent reporters

  • FRET-based sensors for real-time monitoring of phosphorylation

  • Optogenetic tools to induce phosphorylation or dephosphorylation

• Advanced structural biology techniques:

  • Cryo-EM to determine structural changes induced by phosphorylation

  • Hydrogen-deuterium exchange mass spectrometry to identify conformational changes

  • AlphaFold or other AI-based structural prediction to model phosphorylation effects

How might differences in S142 phosphorylation contribute to hematological disorders?

While the search results don't directly address the role of S142 phosphorylation in hematological disorders, we can extrapolate potential connections based on GATA1's known functions:

• GATA1 mutations in disease:

  • Mutations in GATA1 have been associated with X-linked dyserythropoietic anemia and thrombocytopenia

  • Acquired somatic mutations in GATA1 occur in virtually all children with Down's Syndrome, congenital transient myeloproliferative syndrome (TMD), and acute megakaryocytic leukemia

• Phosphorylation dysregulation hypotheses:

  • Altered phosphorylation at S142 could potentially affect GATA1's transcriptional activity

  • This might disrupt the balance between erythroid and megakaryocytic differentiation

  • Could affect interaction with regulatory partners like FOG-1

• Compensatory mechanisms:

  • Research with phospho-mutant mice suggests compensatory mechanisms exist in normal development

  • These mechanisms might fail under disease conditions or genetic backgrounds

  • The moderate decrease in BFU-E and CFU-E progenitor populations in the triple mutant mice might become more significant in disease contexts

• Therapeutic implications:

  • Understanding phosphorylation regulation could lead to targeted therapies

  • Kinase inhibitors targeting the relevant kinases could modulate GATA1 function

  • Phosphatase modulators might restore normal phosphorylation patterns

• Context-dependent effects:

  • The importance of S142 phosphorylation might be heightened in specific disease contexts

  • Stress conditions or inflammatory environments might expose phenotypes not seen under normal conditions

  • Genetic background effects might interact with phosphorylation status

Further research specifically examining S142 phosphorylation in patient samples with various hematological disorders would be needed to establish direct connections.

What experimental systems would best advance our understanding of GATA1 phosphorylation dynamics?

To advance understanding of GATA1 phosphorylation dynamics, several experimental systems would be valuable:

• Time-resolved phosphorylation studies:

  • Synchronized cell systems to track phosphorylation changes during cell cycle

  • Differentiation time courses using primary erythroid progenitors or cell lines

  • Pulse-chase experiments to determine phosphorylation turnover rates

• Improved genetic models:

  • CRISPR-engineered cell lines with phosphomimetic mutations (S142D/E)

  • Conditional phospho-mutant mouse models for tissue-specific analysis

  • Humanized mouse models carrying patient-derived GATA1 mutations

• Human iPSC-derived systems:

  • iPSC-derived erythroid and megakaryocytic differentiation models

  • GATA1-knockout iPSCs (as used in neutrophil studies) adapted for erythroid lineage

  • Patient-derived iPSCs with GATA1 mutations to study phosphorylation effects

• In vitro reconstitution systems:

  • Purified components to study GATA1 phosphorylation by candidate kinases

  • Reconstituted transcription complexes to assess functional effects

  • Cell-free transcription systems to isolate direct effects

• Stress and perturbation studies:

  • Challenge systems with erythropoietic stress (beyond PHZ models)

  • Combine with inflammatory stimuli or hypoxia to reveal context-specific roles

  • Drug perturbations targeting kinases and phosphatases

• Integrative approaches:

  • Multi-omics studies combining phosphoproteomics, transcriptomics, and chromatin studies

  • Mathematical modeling of phosphorylation networks

  • Systems biology approaches to map GATA1 phosphorylation in broader cellular signaling contexts

• Organoid and ex vivo systems:

  • Bone marrow organoids to study phosphorylation in more physiological context

  • Ex vivo culture of primary cells with phosphatase inhibitors to preserve in vivo phosphorylation status

  • Co-culture systems to examine cell-cell interaction effects on phosphorylation

These approaches, especially when combined, would provide comprehensive insights into the dynamics, regulation, and functional consequences of GATA1 phosphorylation at S142.